Venetoclax was granted approval in combination with azacitidine, decitabine, or low dose cytarabine earlier this month for adults 75 years or older with newly diagnosed acute myeloid leukemia or those who have comorbidities precluding intensive induction chemotherapy.
The updated guidelines outlined indications and best practices for pelvic radiation treatments, as well as the integration of radiation with chemotherapy and surgery for patients with stage II to III disease.
This study found that the impact of COVID-19 on cancer care in the US has led to decreases and delays in identifying new cancers, as well as the delivery of treatment.
The FDA approved expanded claims for the cobas EGFR Mutation Test v2 as a companion diagnostic for a broader group of therapies in the treatment of non-small cell lung cancer.
Patients who participated in the Beat AML Master clinical trial were found to have superior outcomes with precision medicine, compared to patients with acute myeloid leukemia who opted for standard chemotherapy treatment.
A study led by Jefferson researchers found that not all patients, specifically African American patients and women without private insurance, receive the same breast cancer treatment, specifically the beneficial and more cost-effective hypofractionated whole breast radiation therapy.